Ich habe diese Aktie im Depot und bin im Minus. Gestern gings stark bergab und wollte mal eure Meinung zu dieser Firma hören. Momentan ist sie bei ca. 0.50$ mit Kursziel von 3$. Seht ihr da eine Chance das hier längerfristig doch noch was wird?
hier noch n paar infos:
Hythiam, Inc. is a healthcare services management company, providing through its Catasys subsidiary behavioral health management services for substance abuse to health plans. Catasys is focused on offering integrated substance dependence solutions, including its PROMETA Treatment Program, for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers and Company managed treatment centers that offer the PROMETA Treatment Program, as well as other treatments for substance dependencies. It also researches, develops, licenses and commercializes and physiological, nutritional, and behavioral treatment programs. On January 20, 2009, the Company sold its interest in Comprehensive Care Corporation (CompCare), a behavioral health managed care company.
Q2 (Jun '09) 2008
Net profit margin -1327.76% -122.28%
Operating margin -1244.74% -130.01%
EBITD margin - -123.22%
Return on a. assets -98.86% -98.37%
Return on a. equity -511.34% -227.25%
Die letzten aussagekräftigen News vom 17.09.09 als ich gekauft habe waren:
Hythiam, Inc. (NASDAQ:HYTM) announced today that the Company has entered into a three year agreement with Ford® Motor Company to provide the Catasys® integrated substance dependence solution to Ford’s hourly employees in Michigan enrolled in the National PPO and who meet certain criteria. Eligible employees struggling with alcoholism, stimulant and opiate dependence will be covered under the program, which contains medical interventions including naltrexone, Suboxone® and the proprietary PROMETA® Treatment Program, and psychosocial and care coaching components across 52 weeks. The Company will conduct direct outreach to enroll qualified members, and will also work with UAW-Ford and Ford’s EAP program to ensure the most beneficial treatment pathway for members. Contractual revenues from the agreement are based on a combination of monthly fees for the member population for Catasys, with additional monthly fees for members enrolled into the Catasys program. Operational implementation is expected to begin shortly, and the program is anticipated to launch in the fourth quarter of 2009.
“We are pleased by the level of support we received from UAW-Ford and Ford’s management personnel,” said Terren Peizer, Hythiam’s Chairman and CEO. “Our ability to engage and contract with employers and health plans highlights the flexibility of our program to address substance dependence challenges faced by diverse payors and their member populations. We have realigned our company and developed Catasys for the managed care market, and it is rewarding to have a new agreement that further publicly validates our product and business model. Ford’s desire to improve employee care and productivity demonstrates a significant opportunity for health plans to provide their customers the Catasys solution. We look forward to additional agreements over the coming months, and we remain focused on providing effective solutions that enhance member care and improve clinical outcomes, resulting in lower total health care costs. This is especially important as payors face multiple challenges including the recently passed mental health parity and addiction equity bill (Wellstone Domenici Mental Health Parity and Addiction Equity Act of 2008), and increasing budgetary constraints at a time of rising substance dependence rates due to the current economic environment.”